Telitacicept Reduces SLE Severity in Phase 3 Trial in China
Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company announced. “We are delighted with the news of the preliminary results of the Phase III confirmatory study of our proprietary…